Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes.
Yusuke MutoYumi KambayashiHiroshi KatoSatoru MizuhashiTakamichi ItoTakeo MaekawaShoichiro IshizukiHiroshi UchiShigeto MatsushitaYuki YamamotoKoji YoshinoYasuhiro FujisawaRyo AmagaiKentaro OhuchiAkira HashimotoSatoshi FukushimaYoshihide AsanoTaku FujimuraPublished in: Cancers (2024)
This study suggests that adjuvant therapy is more effective with non-acral cutaneous melanoma than either the acral or mucosal types at the 3-year TTR endpoint.
Keyphrases